Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

Journal of Medicinal Chemistry

Volumn 47, Issue 4, 2004, Pages 935-946

  Polychronopoulos, Panagiotis ^a   Magiatis, Prokopios ^a   Skaltsounis, Alexios Leandros ^a   Myrianthopoulos, Vassilios ^a   Mikros, Emmanuel ^a   Tarricone, Aldo ^b   Musacchio, Andrea ^b   Roe, S Mark ^c   Pearl, Laurence ^c   Leost, Maryse ^d   Greengard, Paul ^e   Meijer, Laurent ^d,e  

^a UNIVERSITY OF ATHENS   (Greece)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d STATION BIOLOGIQUE   (France)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN; INDIRUBIN DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; MOLECULAR MODEL; STRUCTURE ANALYSIS;

CYCLIN-DEPENDENT KINASES; GLYCOGEN SYNTHASE KINASE 3; INDOLES; MODELS, MOLECULAR; OXIMES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2442589341     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031016d     Document Type: Article

References (54)

1. Cohen, P. The role of protein phosphorylation in human health and disease. Eur. J. Biochem. 2001, 268, 5001-5010.
2. Cohen, P. Protein kinases - the major drug target of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315.
3. Garcia-Echeverria, C.; Traxler, P.; Evans, D. B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 2000, 20, 28-57.
4. Sridhar, R.; Hanson-Painton, O.; Cooper, D. R. Protein kinases as therapeutic targets. Pharmaceut. Res. 2000, 17, 1345-1353.
5. Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997-2000. Exp. Opin. Ther. Pat. 2001, 11, 405-429.
6. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanan, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
7. Malumbres, M.; Ortega, S.; Barbacid, M. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol. Chem. 2000, 381, 827-838.
8. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1, 222-231.
9. Ortega, S.; Malumbres, M.; Barbacid, M. Cyclin D -dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 2002, 1602, 73-87.
10. Dhavan, R.; Tsai, L.-H. A decade of CDK5. Nature Rev. Mol. Cell Biol. 2001, 2, 749-759.
11. Maccioni, R. B.; Otth, C.; Concha, I. I.; Munoz, J. P. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur. J. Biochem. 2001, 268, 1518-1527.
12. Smith, D. S.; Tsai, L. H. Cdk5 behind the wheel: a role in trafficking and transport ? Trends Cell Biol. 2002, 12, 28-36.
13. Nikoulina, S. E.; Ciaraldi, T. P.; Mudaliar, S.; Carter, L.; Johnson, K. ; Henry, R. R. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 2002, 51, 2190-2198.
14. Eldar-Finkelman, H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Medic. 2002, 8, 126-132.
15. Kaytor, M. D.; Orr, H. T. The GSK-3β signaling cascade and neurodegenerative disease. Curr. Opinion Neurobiol. 2002, 12, 275-278.
16. De Strooper, B.; Woodgett, J. Mental plaque removal. Nature 2003, 423, 392-393.
17. Noble, W.; Olm, V.; Takata, K.; Casey, E.; Mary, O. Meyerson, J.; Gaynor, K.; LaFrancois, J.; Wang, L.; Kondo, T.; Davies, P.; Burns, M.; Veeranna, Nixon, R.; Dickson, D.; Matsuoka, Y.; Ahlijanian, M.; Lau, L. F. and Duff, K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38, 555-565.
18. Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klein, P. S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423, 435-439.
19. Hardcastle, I. R.; Golding, B. T.; Griffin, R. J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325-348.
20. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
21. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Medic. 2002, 8, S32-S37.
22. Fischer, L.; Endicott, J.; Meijer, L. Cyclin-dependent kinase inhibitors. In Cell Cycle Regulators as Therapeutic Targets Meijer, L.; Jézéquel, A.; Roberge, M., Eds., Progress in Cell Cycle Research: Editions "Life in Progress", Station Biologique de Roscoff, 2003; Vol. 5, pp 235-248.
23. Dorronsoro, I.; Castrob, A.; Martinez, A. Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? Expert Opin. Ther. Pat. 2002, 12, 1-10.
24. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medic. Res. Rev. 2002, 22, 373-384.
25. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, JA.; Snyder, GL. ; Greengard, P.; Biernat, J.; Mandelkow, E.-M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase - 3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most CDK inhibitors? J. Biol. Chem. 2001, 276, 251-260.
26. Hoessel, R.; Leclerc, S.; Endicott, J.; Noble, M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin.; the active constituent of a Chinese antileukaemia medicine.; inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
27. Balfour-Paul, J. Indigo; British Museum Press: London, 1998; 1-264.
28. Cooksey, C. J. Tyrian purple: 6,6′-Dibromoindigo and Related Compounds. Molecules 2001, 6, 736-769.
29. Adachi, J.; Mori, Y.; Matsui, S.; Takigami, H.; Fujino, J.; Kitagawa, H. ; Miller, C. A. 3rd, Kato, T.; Saeki, K.; Matsuda, T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 2001, 276, 31475-31478.
30. Gillam, E. M. J.; Notley, L. M.; Cai, H.; DeVoss, J. J.; Guengerich, F. P. Oxidation of indole by cytochrome P450 enzymes. Biochem. 2000, 39, 13817-13824.
31. MacNeil, I. A.; Tiong, C. L.; Minor, C.; August, P. R.; Grossman, T. H.; Loiacono, K. A.; Lynch, B. A.; Phillips, T.; Narula, S.; Sundaramoorthi, R.; Tyler, A.; Aldredge, T.; Long, H.; Gilman, M.; Holt, D.; Osburne, M. S. Expression and isolation of antimicrobial small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol. 2001, 3, 301-308.
32. Tang, W.; Eisenbrand, G. Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modern medicine; Springer-Verlag: Heidelberg, 1992.
33. Xiao, Z.; Hao, Y.; Liu, B.; Qian, L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 2002, 43, 1763-1768.
34. Damiens, E.; Baratte, B.; Marie, D.; Eisenbrand, G.; Meijer, L. Anti-mitotic properties of indirubin-3′-oxime.; a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 2001, 20, 3786-3797.
35. Marko, D.; Schätzle, S.; Friedel, A.; Genzlinger, A.; Zankl, H.; Meijer, L.; Eisenbrand, G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumor cells. Br. J. Cancer 2001, 84, 283-289.
36. Elferink, C. J. Aryl hydrocarbon receptor-mediated cell cycle control. In Cell Cycle Regulators as Therapeutic Targets; Meijer, L.; Jezequel, A.; Roberge, M. Eds; Progress in Cell Cycle Research: Editions "Life in Progress", Station Biologique de Roscoff, 2003; Vol. 5, pp 261-267.
37. Andersson, P.; McGuire, J.; Rubio, C.; Gradin, K.; Whitelaw, ML.; Pettersson, S.; Hanberg, A.; Poellinger, L. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 9990-9995.
38. Bradshaw, T. D.; Trapani, V.; Vasselin, D. A.; Westwell, A. D. The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe? Curr. Pharmacol. Design 2002, 8, 2475-2490.
39. Koliopanos, A.; Kleeff, J.; Xiao, Y.; Safe, S.; Zimmermann, A.; Buchler, M. W.; Friess, H. Increased aryl hydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 2002, 21, 6059-6070.
40. Safe, S.; McDougal, A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers. Int. J. Oncol. 2002, 22, 1123-1128.
41. Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; Endicott, J. A.; Noble, M. E. M. Inhibitor binding to active and inactive CDK2. The crystal structure of a CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001, 9, 389-397.
42. Clark, R. J. H.; Cooksey, C. J. Bromoindirubins: the synthesis and properties of minor components of tyrian purple and the composition of the colorant from Nucella lapillus. J. Soc. Dyers Colour. 1997, 113, 316-321.
43. Noland, W.; Rieke, R. New synthetic route to 6-nitroisatin via nitration of 3-indolealdehyde. J. Org. Chem. 1962, 27, 2250-2252.
44. Vedani, A.; Zbinden, P.; Snyder, J.; Greenidge, P. Pseudoreceptor Modeling: The Construction of Three-Dimensional Receptor Surrogates. J. Am. Chem. Soc. 1995, 117, 4987-4994.
45. De Bondt, H. L.; Rosenblatt, J.; Jancaric, J.; Jones, H. D.; Morgan, D. O.; Kim, S. H. Crystal structure of cyclin-dependend kinase 2. Nature, 1993, 363, 595-602.
46. Davies, T. G.; Pratt, D. J.; Endicott, J. A.; Johnson, L. N.; Noble, M. E. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 2002, 93, 125-133.
47. Knockaert, M.; Meijer, L. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochem. Pharmacol. 2002, 64, 819-825.
48. Droucheau, E.; Primor, A.; Thomas, V.; Mattei, D.; Knockaert, M.; Richardson, C.; Sallicandro, P.; Alano, P.; Jafarshad, A.; Baratte, B.; Kunick, C.; Parzy, D.; Pearl, L.; Doerig, C.; Meijer, L. Plasmodium falciparum glycogen synthase kinase-3, molecular model, expression, intracellular localisation and selective inhibitors. Biochim. Biophys. Acta 2003, in press.
49. Doerig, C.; Meijer, L.; Mottram, J. C. Protein kinases as drug targets of parasitic protozoa. Trends Parasitol. 2002, 18, 366-371.
50. Primot, A.; Baratte, B.; Gompel, M.; Borgne, A.; Liabeuf, S.; Romette, J. L.; Costantini, F.; Meijer, L. Purification of GSK-3 by affinity chromatography on immobilised axin. Protein Expr. Purif. 2000, 20, 394-404.
51. cdc2 on its Thr-14 and Tyr-15 residues at the prophase/metaphase transition. J. Biol. Chem. 1996, 271, 27847-27854.
52. Mohamadi, F.; Richards, N. G. J. Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-An intergrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
53. Stewart, J. J. P. MOPAC-a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
54. nck5a complex. Mol. Cell 2001, 8, 657-669.